DE69941598D1 - Anti-ccr2 antikörper sowie deren verwendung - Google Patents
Anti-ccr2 antikörper sowie deren verwendungInfo
- Publication number
- DE69941598D1 DE69941598D1 DE69941598T DE69941598T DE69941598D1 DE 69941598 D1 DE69941598 D1 DE 69941598D1 DE 69941598 T DE69941598 T DE 69941598T DE 69941598 T DE69941598 T DE 69941598T DE 69941598 D1 DE69941598 D1 DE 69941598D1
- Authority
- DE
- Germany
- Prior art keywords
- receptor
- ccr2
- ligand
- antibodies
- mammalian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/121,781 US6312689B1 (en) | 1998-07-23 | 1998-07-23 | Anti-CCR2 antibodies and methods of use therefor |
PCT/US1999/016452 WO2000005265A2 (en) | 1998-07-23 | 1999-07-22 | Anti-crr2 antibodies and methods of use therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69941598D1 true DE69941598D1 (de) | 2009-12-10 |
Family
ID=22398750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69941598T Expired - Lifetime DE69941598D1 (de) | 1998-07-23 | 1999-07-22 | Anti-ccr2 antikörper sowie deren verwendung |
Country Status (9)
Country | Link |
---|---|
US (16) | US6312689B1 (de) |
EP (2) | EP2058333A2 (de) |
JP (3) | JP4057243B2 (de) |
AT (1) | ATE446973T1 (de) |
AU (4) | AU764825B2 (de) |
CA (1) | CA2336250C (de) |
DE (1) | DE69941598D1 (de) |
ES (1) | ES2335948T3 (de) |
WO (1) | WO2000005265A2 (de) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69535327T2 (de) * | 1994-01-13 | 2007-06-06 | The Regents Of The University Of California, Oakland | Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung |
US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6696550B2 (en) * | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6610834B1 (en) * | 1998-11-18 | 2003-08-26 | Peter I. Lobo | Human IgM antibodies to chemokine receptors |
EP1118858A3 (de) * | 2000-01-12 | 2003-07-09 | Pfizer Limited | Testverfahren |
AU2004208716B2 (en) * | 2000-02-03 | 2007-01-04 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
ES2293973T3 (es) * | 2000-02-03 | 2008-04-01 | Millennium Pharm Inc | Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos. |
EP1783227A1 (de) * | 2000-02-03 | 2007-05-09 | Millennium Pharmaceuticals, Inc. | Humanisierte Antikörper gegen CCR2 und Verfahren zur deren Verwendung |
GB0004183D0 (en) * | 2000-02-22 | 2000-04-12 | Smithkline Beecham Plc | New use |
WO2001070266A2 (en) * | 2000-03-17 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
US20030211105A1 (en) * | 2001-05-18 | 2003-11-13 | Murphy William J | Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity |
ES2274041T3 (es) * | 2001-06-07 | 2007-05-16 | Chemocentryx, Inc. | Ensayo de migracion celular. |
US7468253B2 (en) * | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
US20040151721A1 (en) * | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
US7053202B2 (en) * | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
AU2002357770B2 (en) | 2001-11-30 | 2008-07-31 | Biogen Ma Inc. | Antibodies against monocyte chemotactic proteins |
EP2075256A2 (de) | 2002-01-14 | 2009-07-01 | William Herman | Gezielte Liganden |
CA2478803A1 (en) | 2002-03-15 | 2003-09-25 | Schering Corporation | Methods of modulating cd200 receptors |
US7230008B2 (en) * | 2002-04-29 | 2007-06-12 | Merck & Co, Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
TWI262077B (en) * | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
US20060030582A1 (en) * | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
DE60321333D1 (de) | 2002-04-29 | 2008-07-10 | Merck Sharp & Dohme | Tetrahydropyranyl-cyclopentyl-tetrahydropyridopyridin-modulatoren der chemokin-rezeptor-aktivität |
US7285270B2 (en) * | 2002-07-31 | 2007-10-23 | Trustees Of Dartmouth College | Method of reducing neuropathic pain |
US7888479B2 (en) | 2002-11-27 | 2011-02-15 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactric proteins |
KR100895968B1 (ko) | 2002-11-27 | 2009-05-07 | 인사이트 코포레이션 | 케모킨 수용체의 조절자로서의 3-아미노피롤리딘 유도체 |
NZ543287A (en) * | 2003-04-15 | 2008-08-29 | Merck & Co Inc | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
US20050202029A1 (en) * | 2003-10-03 | 2005-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Family of cystatin-related chemoattractant proteins |
JP2007521248A (ja) | 2003-12-10 | 2007-08-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヒト化抗ccr2抗体および該抗体を使用する方法 |
HU229709B1 (en) | 2004-04-13 | 2014-05-28 | Incyte Corp Wilmington | Piperazinyilpiperidine derivatives as chemokine receptor antagonists |
WO2005101002A1 (en) * | 2004-04-13 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 2 (ccr2) |
CA2575612A1 (en) * | 2004-07-30 | 2006-02-09 | Pfizer Products Inc. | Methods of treating ccr2 mediated diseases or disorders |
AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
DE102006015341A1 (de) * | 2006-04-03 | 2007-10-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Behandlung von multipler Sklerose und/oder rheumatoider Arthritis |
US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
US20100074886A1 (en) * | 2006-10-05 | 2010-03-25 | Anuk Das | Ccr2 antagonists for treatment of fibrosis |
PE20081785A1 (es) * | 2007-02-19 | 2009-01-12 | Novartis Ag | Derivados de ciclohexil-amida del acido aril carboxilico |
EP2124996A4 (de) | 2007-02-20 | 2010-03-24 | Merrimack Pharmaceuticals Inc | Verfahren zur behandlung von multipler sklerose mittels verabreichung eines alpha-fetoproteins in kombination mit einem integrinantagonisten |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
SG193216A1 (en) | 2008-08-18 | 2013-09-30 | Amgen Fremont Inc | Antibodies to ccr2 |
EP2161072A1 (de) * | 2008-09-03 | 2010-03-10 | Gambro Lundia AB | Hämodialysemembranen mit einem hohen Cut-off zur Behandlung von Patienten mit chronischer Hämodialysis |
PE20110831A1 (es) | 2008-11-26 | 2011-11-20 | Pfizer | 3-aminociclopentanocarboxamidas como moduladores del receptor de quimiocina |
DK3912643T3 (da) | 2009-02-13 | 2022-10-17 | Immunomedics Inc | Immunokonjugater med en intracellulært-spaltelig binding |
US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
RU2560253C2 (ru) | 2009-06-16 | 2015-08-20 | Колгейт-Палмолив Компани | Система, набор и способ ухода за полостью рта |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011019679A1 (en) | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Ccr2 inhibitors for treating conditions of the eye |
EP2478110B1 (de) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Klasse-i-anti-cea-antikörper und verwendungen davon |
WO2011068845A1 (en) | 2009-12-02 | 2011-06-09 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
KR101473539B1 (ko) | 2009-12-23 | 2014-12-16 | 콜게이트-파아므올리브캄파니 | 구강 관리 시스템 |
WO2011078864A1 (en) | 2009-12-23 | 2011-06-30 | Colgate-Palmolive Company | Oral care system |
US8523475B2 (en) | 2009-12-23 | 2013-09-03 | Colgate-Palmolive Company | Oral care system, kit and method |
CN102711554B (zh) | 2009-12-23 | 2014-10-29 | 高露洁-棕榄公司 | 口腔护理系统 |
AU2010333783B2 (en) | 2009-12-23 | 2014-01-30 | Colgate-Palmolive Company | Oral care system |
WO2012114223A1 (en) | 2011-02-25 | 2012-08-30 | Pfizer Limited | A method of treating liver fibrosis |
JP5768147B2 (ja) | 2011-02-28 | 2015-08-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 一価抗原結合タンパク質 |
KR101638224B1 (ko) | 2011-02-28 | 2016-07-08 | 에프. 호프만-라 로슈 아게 | 항원 결합 단백질 |
EP2704751B1 (de) | 2011-05-02 | 2019-04-17 | Immunomedics, Inc. | Ultrafiltrationskonzentration ausgewählter allotypen-antikörper für kleinvolumige verabreichung |
US9434766B2 (en) | 2011-06-27 | 2016-09-06 | Universite Pierre Et Marie Curie (Paris 6) | CCR2 antagonist peptides |
JP6438391B2 (ja) | 2012-06-22 | 2018-12-12 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Ccr2に結合する抗原結合タンパク質 |
US9315567B2 (en) | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
WO2014064192A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction |
PT2900277T (pt) | 2012-12-13 | 2022-05-25 | Immunomedics Inc | Doses de imunoconjugados de anticorpos e sn-38 para melhorar a eficácia e diminuir a toxicidade |
MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
AU2015219495B2 (en) | 2014-02-21 | 2019-11-21 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
EP3160504B1 (de) | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis |
EP3244772B1 (de) | 2015-02-02 | 2023-07-26 | Colgate-Palmolive Company | Mundpflegematerialspender |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
EP3316885B1 (de) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antikörper-sn-38-immunkonjugate mit einem cl2a-linker |
US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
JPWO2022239720A1 (de) | 2021-05-10 | 2022-11-17 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US5292668A (en) | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2006408A1 (en) | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
TW212184B (de) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5182366A (en) | 1990-05-15 | 1993-01-26 | Huebner Verena D | Controlled synthesis of peptide mixtures using mixed resins |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
US5543503A (en) | 1991-03-29 | 1996-08-06 | Genentech Inc. | Antibodies to human IL-8 type A receptor |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
EP0570904B1 (de) * | 1992-05-22 | 1997-08-13 | Makita Corporation | Gehrungssäge |
US5508384A (en) | 1992-09-10 | 1996-04-16 | New York University | Polypeptide derived from a popamine receptor, and compositions and methods thereof |
WO1994009128A1 (en) | 1992-10-22 | 1994-04-28 | Mallinckrodt Medical, Inc. | Therapeutic treatment for inhibiting vascular restenosis |
WO1994012214A1 (en) | 1992-12-01 | 1994-06-09 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
US5468707A (en) | 1992-12-01 | 1995-11-21 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Coordination catalyst systems |
DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
DE4332256C1 (de) | 1993-09-22 | 1995-03-09 | Lipp Martin Dr Dr Habil | Monoklonale Antikörper gegen Leukozyten-spezifische G-Protein-gekoppelte Rezeptoren |
DE69535327T2 (de) | 1994-01-13 | 2007-06-06 | The Regents Of The University Of California, Oakland | Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung |
US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
US6498015B1 (en) | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
JPH09282886A (ja) * | 1996-01-19 | 1997-10-31 | Sgs Thomson Microelectron Inc | メモリセルへの書込の開始をトラッキングする回路及び方法 |
US5864696A (en) * | 1996-01-19 | 1999-01-26 | Stmicroelectronics, Inc. | Circuit and method for setting the time duration of a write to a memory cell |
US7115379B1 (en) * | 1996-01-24 | 2006-10-03 | Schering Corporation | Anti-mammalian CX3C cytokine antibodies |
SE9600820D0 (sv) | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
US5657277A (en) * | 1996-04-23 | 1997-08-12 | Micron Technology, Inc. | Memory device tracking circuit |
AU735460B2 (en) | 1996-06-14 | 2001-07-12 | Aaron Diamond Aids Research Center, The | Uses of a chemokine receptor for inhibiting HIV-1 infection |
CA2288198A1 (en) | 1997-03-25 | 1998-10-01 | Daniel I. Simon | Modulation of vascular healing by inhibition of leukocyte adhesion and function |
ES2187972T3 (es) | 1997-04-04 | 2003-06-16 | Max Planck Gesellschaft | Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes. |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US5858089A (en) * | 1997-08-26 | 1999-01-12 | Martinovic; Zoran | Corn buttering tool |
US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US6696550B2 (en) * | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US20040151721A1 (en) * | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
US7053202B2 (en) * | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
-
1998
- 1998-07-23 US US09/121,781 patent/US6312689B1/en not_active Expired - Lifetime
-
1999
- 1999-07-22 ES ES99937353T patent/ES2335948T3/es not_active Expired - Lifetime
- 1999-07-22 EP EP09000493A patent/EP2058333A2/de not_active Withdrawn
- 1999-07-22 EP EP99937353A patent/EP1098908B1/de not_active Expired - Lifetime
- 1999-07-22 WO PCT/US1999/016452 patent/WO2000005265A2/en active Application Filing
- 1999-07-22 CA CA2336250A patent/CA2336250C/en not_active Expired - Lifetime
- 1999-07-22 DE DE69941598T patent/DE69941598D1/de not_active Expired - Lifetime
- 1999-07-22 AT AT99937353T patent/ATE446973T1/de active
- 1999-07-22 US US09/359,193 patent/US6352832B1/en not_active Expired - Lifetime
- 1999-07-22 JP JP2000561221A patent/JP4057243B2/ja not_active Expired - Lifetime
- 1999-07-22 AU AU52208/99A patent/AU764825B2/en not_active Expired
-
2001
- 2001-05-29 US US09/866,970 patent/US6458353B1/en not_active Expired - Lifetime
- 2001-06-29 US US09/895,723 patent/US6491915B2/en not_active Expired - Lifetime
- 2001-06-29 US US09/896,309 patent/US6406694B1/en not_active Expired - Lifetime
- 2001-07-03 US US09/898,513 patent/US20030165494A1/en not_active Abandoned
- 2001-07-13 US US09/905,835 patent/US6395497B1/en not_active Expired - Lifetime
- 2001-07-13 US US09/905,847 patent/US6406865B2/en not_active Expired - Lifetime
- 2001-07-13 US US09/905,848 patent/US6451522B2/en not_active Expired - Lifetime
- 2001-07-13 US US09/905,849 patent/US6448021B1/en not_active Expired - Lifetime
-
2003
- 2003-07-14 AU AU2003213475A patent/AU2003213475B2/en not_active Expired
- 2003-09-05 US US10/656,805 patent/US7566539B2/en not_active Expired - Fee Related
-
2004
- 2004-04-16 US US10/826,454 patent/US20040265303A1/en not_active Abandoned
-
2006
- 2006-09-01 AU AU2006206064A patent/AU2006206064B2/en not_active Expired
-
2007
- 2007-04-26 JP JP2007117804A patent/JP2007262074A/ja not_active Withdrawn
- 2007-10-25 US US11/924,153 patent/US20080241923A1/en not_active Abandoned
- 2007-10-25 US US11/924,091 patent/US20080268536A1/en not_active Abandoned
- 2007-10-26 US US11/924,783 patent/US20090142339A1/en not_active Abandoned
- 2007-10-26 US US11/924,794 patent/US7566450B2/en not_active Expired - Fee Related
-
2008
- 2008-12-24 JP JP2008328813A patent/JP2009143926A/ja active Pending
-
2009
- 2009-03-02 AU AU2009200820A patent/AU2009200820A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69941598D1 (de) | Anti-ccr2 antikörper sowie deren verwendung | |
ATE373719T1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
DE69129743D1 (de) | Humanisierte chimäre anti-"icam-1" antikörper, herstellungsverfahren und verwendung | |
BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
ATE159982T1 (de) | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung | |
SG44845A1 (en) | Recombitant anti-vla4 antibody molecules | |
ATE353920T1 (de) | Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie | |
DE69418284D1 (de) | Vorrichtung zur analyse von haptenen und ihre verwendung | |
EP1411962A4 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
WO1999046379A3 (en) | Human receptor proteins; related reagents and methods | |
TR200102877T2 (tr) | İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar. | |
CA2185112A1 (en) | Humanized monoclonal antibodies against human interleukin-4 | |
ATE248189T1 (de) | Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung | |
WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
WO2005060368A3 (en) | Humanized anti-ccr2 antibodies and methods of use | |
ATE359821T1 (de) | Bor-neutronenfangtherapie unter verwendung von pre-targeting-methoden | |
WO1999035266A3 (en) | Human urotensin ii | |
YU46858B (sh) | Postupak za dobijanje imunoglobulinskih konjugata | |
ATE139704T1 (de) | Verwendung und verabreichung von enzymen | |
ATE490271T1 (de) | Rezeptor, dessen verwendung sowie mausantikörper | |
WO1996040250A3 (en) | Platelet-specific chimeric immunoglobulin and methods of use therefor | |
IL108811A0 (en) | Immunoassay reagents, kits and methods | |
DE60045637D1 (de) | Nicotin-acetylcholin rezeptoruntereinheit, deren isolierung und verwendung | |
DE69229948T2 (de) | hGPIIb-FRAGMENTE UND IHRE VERWENDUNG IN IN-VITRO-VERFAHREN ZUR BESTIMMUNG VON IN VIVO STATTFINDENDEN THROMBOTISCHEN EREIGNISSEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |